Perlecan-Induced Suppression of Smooth Muscle Cell Proliferation Is Mediated Through Increased Activity of the Tumor Suppressor PTEN

Circulation Research

Volumn 94, Issue 2, 2004, Pages 175-183

  Garl, Pamela J ^a   Wenzlau, Janet M ^a   Walker, Heather A ^a   Whitelock, John M ^b   Costell, Mercedes ^c   Weiser Evans, Mary C M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Basement membrane; Restenosis; Smooth muscle cell proliferation; Vascular development; Vascular injury

Indexed keywords

COMPLEMENTARY DNA; DNA; FIBRONECTIN; FOCAL ADHESION KINASE; MORPHOLINE; PERLECAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BASEMENT MEMBRANE; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CELL CULTURE; CELL DIVISION; CELL PROLIFERATION; CULTURE MEDIUM; DNA SYNTHESIS; EMBRYO; ENZYME PHOSPHORYLATION; HETEROZYGOTE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; RESTENOSIS; SERUM; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

ANIMALS; AORTA, THORACIC; BALLOON DILATATION; BASEMENT MEMBRANE; CAROTID ARTERY INJURIES; CELL DIVISION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DNA REPLICATION; FIBRONECTINS; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GLYCOSAMINOGLYCANS; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS;

EID: 1042302787     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000109791.69181.B6     Document Type: Article

References (45)

1. Cook CL, Weiser MCM, Schwartz PE, Jones CL, Majack RA. Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. Circ Res. 1994;74:189-196.
2. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
3. Weiser-Evans MCM, Quinn BE, Burkard MR, Stenmark KR. Transient reexpression of an embryonic autonomous growth phenotype by adult carotid artery SMC following vascular injury. J Cell Physiol. 2000;182:12-23.
4. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991;68:106-113.
5. Weiser MCM, Majack RA, Tucker A, Orton EC. Static tension is associated with increased smooth muscle cell DNA synthesis in rat pulmonary arteries. Am J Physiol. 1995;268:H1133-H1138.
6. Heickendorff L. The basement membrane of arterial smooth muscle cells. APMIS. 1989(suppl)9:1-32.
7. Weiser MCM, Belknap JK, Grieshaber SS, Kinsella MG, Majack RA. Developmental regulation of perlecan gene expression in aortic smooth muscle cells. Matrix Biol. 1996;15:331-340.
8. Weiser MCM, Schwartz PE, Grieshaber NA, Majack RA. Perlecan regulates Oct-1 gene expression in vascular smooth muscle cells. Mol Biol Cell. 1997;8:999-1011.
9. Belknap JK, Weiser-Evans MCM, Grieshaber SS, Majack RA, Stenmark KR. Relationship between perlecan and tropoelastin gene expression and cell replication in the developing rat pulmonary vasculature. Respir Cell Mol Biol. 1999;20:24-34.
10. Walker HA, Whitelock JM, Garl PJ, Nemenoff RA, Stenmark KR, Weiser-Evans MCM. Perlecan upregulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell 2003;14:1941-1952.
11. Kleinman HK, McGarvey ML, Hassell ML Jr, Star VL, Cannon FB, Laurie GW, Martin GR. Basement membrane complexes with biological activity. Biochemistry. 1986;25:312-318.
12. Iozzo RV, Cohen JR, Grassel S, Murdoch AD. The biology of perlecan: the multifacted heparan sulfate proteoglycan of basement membranes and pericellular matrices. Biochem J. 1994;302:625-639.
13. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet. 1999;23:354-358.
14. Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fassler R. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol. 1999;147:1109-1122.
15. Costell M, Carmona R, Gustafsson E, González-Iriarte M, Fässler R, Muñoz-Chápuli R. Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ Res. 2002;91:158-164.
16. Kinsella MG, Tran PK, Weiser-Evans MC, Reidy M, Majack RA, Wight TN. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol. 2003;23:608-614.
17. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 1998;95:15587-15591.
18. Tamura M, Gu J, Damen EH, Takino T, Miyamoto S, Yamada KM. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol-3-kinase/Akt cell survival pathway. J Biol Chem. 1999;274:20693-20703.
19. Dahia PLM. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer. 2000;7:115-129.
20. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci. 2001;114:2375-2382.
21. DiCristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. PTEN is essential for embryonic development and tumor suppression. Nat Genet. 1998;19:348-355.
22. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998;8:1169-1178.
23. Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MCM. A unique highly proliferative growth phenotype expressed by embryonic and neointimal SMC is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. Circulation. In press.
24. Huang J, Kontos CD. Inhibition of vascular smooth muscle cell proliferation, migration, and survival by the tumor suppressor protein PTEN. Arterioscler Thromb Vasc Biol. 2002;22:745-751.
25. Vazque F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 2000;20:5010-5018.
26. Vazquez F, Grossman S, Takahashi Y, Rokas M, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001;276:48627-48630.
27. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000;20:8969-8982.
28. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
29. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA. 1991;88:3739-3743.
30. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
31. Whitelock JM, Murdoch AD, Iozzo RV, Underwod PA. The degradation of human endothelial cell-derived perlecan and release of bound fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 1996;271:10079-10086.
32. Shigematsu K, Koyama H, Olson NE, Cho A, Reidy MA. Phosphatidylinositol 3-kinase signaling is important for smooth muscle cell replication after arterial injury. Arterioscler Thromb Vasc Biol. 2000;20:2373-2378.
33. Weiser-Evans MCM, Schwartz PE, Grieshaber NA, Quinn BE, Grieshaber SS, Belknap JK, Mourani PM, Majack RA, Stenmark KR. Novel embryonic genes are preferentially expressed by autonomously replicating rat embryonic and neointimal smooth muscle cells. Circ Res. 2000;87:608-615.
34. Clowes AW, Kamovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265:625-626.
35. Castellot JJ, Addonizio ML, Rosenberg RD, Karnovsky MJ. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol. 1981;90:372-379.
36. Fritze LM, Reilly CF, Rosenberg RD. An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol. 1985;100:1041-1049.
37. Bingley JA, Hayward IP, Campbell JH, Campbell GR. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J Vasc Surg. 1998;28:308-318.
38. Nugent MA, Nugent HM, Iozzo RV, Sanchack K, Edelman ER. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA. 2000;97:6722-6727.
39. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, Underwood PA. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol. 1999;18:163-178.
40. Lundmark K, Tran PK, Kinsella MG, Clowes AW, Wight TN, Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. J Cell Physiol. 2001;188:67-74.
41. Peng HB, Ali AA, Daggett DF, Rauvala H, Hassell JR, Smalheiser NR. The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction. Cell Adhes Commun. 1998;5:475-489.
42. Hayashi K, Madri JA, Yurchenco PD. Endothelial cells interact with the core protein of basement membrane perlecan through β1 and β3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol. 1992;119:945-959.
43. Taylor JM, Mack CP, Nolan K, Regan CP, Owens GK, Parsons JT. Selective expression of an endogenous inhibitor of FAK regulates proliferation and migration of vascular smooth muscle cells. Mol Cell Biol. 2001;21:1565-1572.
44. Pillarisetti S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med. 2000;10:60-65.
45. Iozzo RV, Pillarisetti J, Sharma B, Murdoch AD, Danielson KG, Uitto J, Mauviel A. Structural and functional characterization of the human perlecan gene promoter: transcriptional activation by transforming growth factor-β via a nuclear factor 1-binding element. J Biol Chem. 1997;272:5219-5228.